XORTX Therapeutics [XRTX] - Last Close: $1.51
A new bout of clinical data is boosting shares of XORTX Therapeutics.
The biopharma firm announced topline results from Part 2 Pharmacokinetics Bridging Study XRX-OXY-101 - Part 2, and the data is promising.
The drug candidate showed a substantial increase in oral bioavailibility of XORTX's proprietary oxypurinol formulation provided with food compared to the fasted state.
Furthermore, the drug produced a clean pharmacologic profile that showed no drug-related adverse or serious side effects related to oral administration of oxypurinol.
XORTX is currently planning a Phase 3 registration clinical trial in autosomal dominant polycystic kidney disease now that the Part 2 trial was a success.
XRTX is trading actively with a 51.0% gain ahead of today's open.
My Take: A drug approval could be ahead for XORTX, but there's always risk in the biopharma industry. The risks could outweigh the rewards after today's rally sent prices soaring. It's possible an approval is largely priced in as of now.
MSP Recovery [MSPR] - Last Close: $2.15
Investors are buzzing about MSP Recover after a recent announcement.
A recent business update from the healthcare record-keeping and data analytics firm revealed the company has grown its pool of unique healthcare members to more than 34 million as of Aug. 11th.
The figure represents tremendous growth from the 11,000 members it had on its roster as of 2014.
MSP Recover also stated it expects to receive data for another 3 million members prior to Sept. 30th.
News of the company's torrid growth has sparked a premarket rally. MSPR is trading actively with a 27.9% gain.
My Take: MSP Recovery has grown at an incredible rate over the past 8 years, but today's move seems somewhat exaggerated. Be cautious if you decide to hop in this one.
